

RECEIVED  
CENTRAL FAX CENTER

JUN 01 2006

Atty. Docket No. 0401-UTL-9 (18528.010)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/016,969

Inventors: PITTNER, Richard A., et al

Filed: December 14, 2001

Title: PEPTIDE YY AND PEPTIDE YY AGONISTS FOR  
TREATMENT OF METABOLIC DISORDERS

Confirmation No.: 7314


TC/A.U.: 1646

Examiner: RUIXIANG, Li

FACSIMILE TRANSMITTAL COVER SHEET

Certificate of Transmission Under 37 C.F.R. 1.8

I hereby certify that the following listed correspondence in the above-referenced application is being transmitted by facsimile to the Commissioner for Patents, Alexandria, VA to telephone number (571) 273-8300 on this 1st day of June 2006.

  
\_\_\_\_\_  
Diane Tras

**Document**

Supplemental Information Disclosure Statement (in duplicate)

PTO/SB08

Reference – Towfigh et al.

No. of Pages

4

2

3

Total No. of Pages Transmitted (including this sheet):

10

RECEIVED

JUN 01 2006

USSN 10/016,969

Atty. Docket No.0401-UTL-0 (18528.010)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/016,969

Inventors: Pittner et al.

Filed: December 14, 2001

Title: PEPTIDE YY AND PEPTIDE YY AGONISTS FOR  
TREATMENT OF METABOLIC DISORDERS

Confirmation No.: 7314

TC/A.U.: 1646

Examiner: Ruixiang Li

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTMail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, Applicant submits a copy of the non-patent reference listed on the attached PTO Form PTO/SB/08 (2 sheets) for consideration by the U.S. Patent and Trademark Office in the above-entitled application and to be made of record herein. In accordance with 37 C.F.R. 1.98, copies of cited U.S. Patents and U.S. Patent Application Publications are not included herewith.

The references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.

---

CERTIFICATE OF FACSIMILE TRANSMISSION UNDER 37 C.F.R. 1.8

---

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the USPTO at facsimile number (571) 273-8300, addressed to Mail Stop Amendment, Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Date of Deposit

June 2006

Signature of Person Mailing Paper


Name of Person Mailing Paper

USSN 10/016,969  
Atty. Docket No.0401-UTL-0 (18528.010)  
Page 2

The Commissioner is hereby authorized to charge Deposit Account No. 01-0535 the amount of \$180.00 as set forth in 37 C.F.R. 1.17(p). Applicant believes no additional fees are due. If Applicant is in error, the Commissioner is hereby authorized to charge any underpayment or credit any overpayment to Deposit Account No. 01-0535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535. A duplicate of this IDS is enclosed for this purpose.

Dated: 1 May 2006

Respectfully Submitted  
AMYLIN PHARMACEUTICALS, INC.

  
\_\_\_\_\_  
Susan J. Myers Fitch, Ph.D.  
Registration No. 55,477

AMYLIN PHARMACEUTICALS, INC.  
9360 Towne Centre Drive  
San Diego, CA 92121  
Telephone: (858) 552-2200  
Facsimile: (858) 552-1936

JUN 01 2006

USSN 10/016,969

Atty. Docket No.0401-UTL-0 (18528.010)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/016,969

Inventors: Pittner et al.

Filed: December 14, 2001

Title: PEPTIDE YY AND PEPTIDE YY AGONISTS FOR  
TREATMENT OF METABOLIC DISORDERS

Confirmation No.: 7314

TC/A.U.: 1646

Examiner: Ruixiang Li

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTMail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, Applicant submits a copy of the non-patent reference listed on the attached PTO Form PTO/SB/08 (2 sheets) for consideration by the U.S. Patent and Trademark Office in the above-entitled application and to be made of record herein. In accordance with 37 C.F.R. 1.98, copies of cited U.S. Patents and U.S. Patent Application Publications are not included herewith.


The references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.

---

CERTIFICATE OF FACSIMILE TRANSMISSION UNDER 37 C.F.R. 1.8

---

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the USPTO at facsimile number (571) 273-8300, addressed to Mail Stop Amendment, Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

1 June 2006  
Date of Deposit  
Signature of Person Mailing PaperDiane Trus  
Name of Person Mailing Paper

JUN 01 2006

USSN 10/016,969


Atty. Docket No.0401-UTL-0 (18528.010)

Page 2

The Commissioner is hereby authorized to charge Deposit Account No. 01-0535 the amount of \$180.00 as set forth in 37 C.F.R. 1.17(p). Applicant believes no additional fees are due. If Applicant is in error, the Commissioner is hereby authorized to charge any underpayment or credit any overpayment to Deposit Account No. 01-0535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535. A duplicate of this IDS is enclosed for this purpose.

Respectfully Submitted  
AMYLIN PHARMACEUTICALS, INC.

Dated: 1 May 2006

  
\_\_\_\_\_  
Susan J. Myers Fitch, Ph.D.  
Registration No. 55,477

AMYLIN PHARMACEUTICALS, INC.  
9360 Towne Centre Drive  
San Diego, CA 92121  
Telephone: (858) 552-2200  
Facsimile: (858) 552-1936

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	10/016,969
Filing Date	December 14, 2001
First Named Inventor	PITTNER, Richard A., et al.
Art Unit	1646
Examiner Name	RUIXIANG LI
Attorney Docket Number	0401-UTL-9(18528.010)

Sheet	1	of	2
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/016,969
		Filing Date	December 14, 2001
		First Named Inventor	Pittner et al.
		Art Unit	1646
		Examiner Name	RUIXIANG, LI
Sheet 2 of 2	Attorney Docket Number	0401-UTL-9 (18528.010)	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Towfigh et al., Surgical Forum Vol. 50: 25-27 (1999).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.